TY - JOUR
T1 - Mutations in polyomavirus middle T antigen affecting tumorigenesis
AU - Gelinas, Celine
AU - Schaffhausen, Brian
AU - Bockus, Beverly
AU - Ratiarson, Annyck
AU - Bastin, Marcel
N1 - Funding Information:
This investigation was supported by grants from the National Cancer Institute of Canada and the Medical Research Council of Canada to M.B. and by a grant from the National Institutes of Health (ROl-CA34722) to B.S. C.G. was the recipient of a fellowship from the National Cancer Institute of Canada. A.R. was supported by a fellowship from the World Health Organization. B.S. is an established investigator of the American Heart Association.
PY - 1989/5
Y1 - 1989/5
N2 - P155 is a polyomavirus mlt mutant with normal transforming ability but impaired tumorigenic potential. The mutation, a 12-bp deletion (nucleotides 1348-1359), removes amino acids 372 to 375 from middle T and affects its ability to function in tumorigenesis (C. Gelinas, S. Masse, and M. Bastin, 1984, J. Virol. 51, 242-246). We used deletion loop mutagenesis to introduce point mutations within the wild-type sequence spanned by the P155 deletion. A mutant phenotype resembling that of P155 could be produced by as little as one alanine to valine substitution at residue 373. The mutants were impaired in their ability to induce tumors in rats but they could still transform established cell lines or primary fibroblasts in culture. To define the biochemical defect, we examined the mutant middle T antigen both for association with pp60c-8rc, the cellular src gene product, as well as its pattern of phosphorylation. No obvious differences explaining the phenotype were observed. The mutant middle T associated with, and activated pp60c-src, but exhibited a slightly altered pattern of phosphorylation, presumably because of additional sites on the middle T protein.
AB - P155 is a polyomavirus mlt mutant with normal transforming ability but impaired tumorigenic potential. The mutation, a 12-bp deletion (nucleotides 1348-1359), removes amino acids 372 to 375 from middle T and affects its ability to function in tumorigenesis (C. Gelinas, S. Masse, and M. Bastin, 1984, J. Virol. 51, 242-246). We used deletion loop mutagenesis to introduce point mutations within the wild-type sequence spanned by the P155 deletion. A mutant phenotype resembling that of P155 could be produced by as little as one alanine to valine substitution at residue 373. The mutants were impaired in their ability to induce tumors in rats but they could still transform established cell lines or primary fibroblasts in culture. To define the biochemical defect, we examined the mutant middle T antigen both for association with pp60c-8rc, the cellular src gene product, as well as its pattern of phosphorylation. No obvious differences explaining the phenotype were observed. The mutant middle T associated with, and activated pp60c-src, but exhibited a slightly altered pattern of phosphorylation, presumably because of additional sites on the middle T protein.
UR - http://www.scopus.com/inward/record.url?scp=0024517667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024517667&partnerID=8YFLogxK
U2 - 10.1016/0042-6822(89)90366-8
DO - 10.1016/0042-6822(89)90366-8
M3 - Article
C2 - 2470192
AN - SCOPUS:0024517667
SN - 0042-6822
VL - 170
SP - 193
EP - 200
JO - Virology
JF - Virology
IS - 1
ER -